Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox's lead program in clinical development is bimatoprost grenod (NCX 470), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox SA generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the United States, and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets.

Employees

Sector

Pharmaceuticals

More about the company

Market Cap	32.52M 37.79M 30.62M 27.9M 52.2M 3.6B 52.41M 363M 140M 1.83B 142M 139M 5.8B	P/E 2026 *	-7.38x	P/E 2027 *	18.5x
Enterprise Value	32.52M 37.79M 30.62M 27.9M 52.2M 3.6B 52.41M 363M 140M 1.83B 142M 139M 5.8B	EV / Sales 2026 *	10.8x	EV / Sales 2027 *	3.25x
Free-Float	99.65%	Yield 2026 *	-	Yield 2027 *	-

Sep. 02	Nicox S.A. Announces Appointment of Doug Hubatsch as Chief Scientific Advisor	CI
Aug. 27	The FDA will issue its decision on Nicox's NCX 470 by the end of next April
Aug. 27	US FDA to Complete Nicox's Glaucoma Drug Review by April 2027	MT
Aug. 27	Nicox S.A. Announces U.S. Food and Drug Administration Accepts the New Drug Application for NCX 470	CI
Aug. 10	Nicox Sa and Ocumension Therapeutics Submit Ncx 470 New Drug Application in China	CI
Aug. 10	Nicox Partner Files China Drug Application for NCX 470 Eye Drop	MT
Aug. 10	A Nicox partner has cleared an important milestone in China
Jul. 01	Nicox Submits NCX 470 New Drug Application In The United States	CI
Jul. 01	Nicox files U.S. marketing approval application
Jun. 23	Nicox Bags EUR6 Million Shareholder Loan	MT
Jun. 23	Nicox Secures Backing From a Shareholder and Financial Partner
Jun. 18	Nicox Receives Positive Feedback from China
Jun. 18	Nicox Announces Positive Pre-Submission Regulatory Feedback in China Supporting NDA Filing for NCX 470	CI

Sep. 02	Nicox Announces Extension of Cash Runway	GL
Aug. 27	Nicox Announces April 2027 PDUFA Date for NCX 470 in Glaucoma	GL
Aug. 10	Nicox Announces NCX 470 NDA Submission in China by Partner Ocumension	GL
Jul. 01	Nicox’s NCX 470 New Drug Application Submitted in the United States by Kowa, with Associated €3 million Milestone Payment	GL
Jun. 23	Nicox and Vester Finance Sign Shareholder Loan Agreement to Support Strategic Activities for the Company	GL

Sep. 02	Un horizon de trésorerie étendu pour Nicox
Sep. 02	Nicox annonce l’extension de son horizon de trésorerie
Aug. 27	Bourse : Pernod Ricard au régime sec, méthode Coué chez Stellantis, la tech américaine se rebiffe
Aug. 27	La FDA rendra sa décision sur le NCX 470 de Nicox d'ici fin avril prochain
Aug. 27	Nvidia, est-ce que ça suffira ?

Manager	Title	Age	Since
Gavin Spencer CEO	Chief Executive Officer	55	2024-02-27
Sandrine Gestin DFI	Director of Finance/CFO	58	2014-12-31
Emmet Purtill PRN	Corporate Officer/Principal	-	2005-12-31

NicOx SA Stock Euronext Paris

Stocks

NCOX

FR0000074130

Pharmaceuticals

Valuation : NicOx SA

Latest news : NicOx SA

Press Releases : NicOx SA

News in other languages : NicOx SA

Quotes and Performance

Managers and Directors : NicOx SA

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Director	Title	Age	Since
Gavin Spencer BRD	Director/Board Member	55	2024-04-07
Damian Marron CHM	Chairman	64	2024-07-15
Marc Bozec BRD	Director/Board Member	-	2024-07-15

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NICOX SA	-7.95%	-9.39%	-	-	37.79M
MERCK & CO., INC.	-0.63%	-2.71%	+74.36%	+35.29%	364B
MERCK KGAA	-1.41%	-5.21%	+21.30%	-19.40%	67.05B
HALOZYME THERAPEUTICS, INC.	-0.85%	-2.07%	+41.17%	+178.86%	12.19B
KYOWA KIRIN CO., LTD.	-0.81%	-9.22%	-12.91%	-15.69%	7.58B
SK BIOPHARMACEUTICALS CO., LTD.	+0.72%	-2.90%	-23.40%	+2.32%	4.9B
YUHAN CORPORATION	+1.14%	-1.60%	-33.28%	+15.07%	4.45B
BETTA PHARMACEUTICALS CO., LTD.	-1.63%	-1.38%	-35.25%	-7.78%	2.96B
SUPERNUS PHARMACEUTICALS, INC.	-0.85%	-4.45%	-8.60%	+37.53%	2.45B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	-1.31%	-2.44%	-25.62%	-19.48%	1.96B
Average	-1.21%	-3.14%	-0.25%	+22.97%	51.95B
Weighted average by Cap.	-0.52%	-1.68%	+60.88%	+29.33%

	2026 *	2027 *
Net sales	3M 3.49M 2.82M 2.57M 4.82M 332M 4.83M 33.48M 12.94M 169M 13.09M 12.81M 535M	10M 11.62M 9.42M 8.58M 16.05M 1.11B 16.12M 112M 43.13M 563M 43.64M 42.69M 1.78B
Net income	-5M -5.81M -4.71M -4.29M -8.03M -553M -8.06M -55.8M -21.57M -282M -21.82M -21.34M -892M	2M 2.32M 1.88M 1.72M 3.21M 221M 3.22M 22.32M 8.63M 113M 8.73M 8.54M 357M
Net Debt	-	-